BamSEC and AlphaSense Join Forces
Learn More

Chinook Therapeutics Inc

Formerly NASDAQ: KDNY
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 21 pages Chinook Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan Adopted by the Board of Directors: March 30, 2015 Approved by the Stockholders: April 1, 2015 Ipo Date/Effective Date: April 15, 2015 as Amended and Restated on June 9, 2023
12/34/56
EX-10.2
from 10-Q 6 pages Amendment No. 1 to Sales Agreement
12/34/56
EX-10.27
from 10-K 8 pages Via Email Alan Glicklich Re:terms of Separation
12/34/56
EX-10.26
from 10-K 58 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Chinook Therapeutics, Inc. if Publicly Disclosed. License Agreement
12/34/56
EX-10.25
from 10-K 56 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Chinook Therapeutics, Inc. if Publicly Disclosed. Shareholders Agreement
12/34/56
EX-10.24
from 10-Q 9 pages 3. Sublease Premises
12/34/56
EX-10.23
from 10-K 10 pages Chinook Therapeutics, Inc. Inducement Stock Option Grant Notice
12/34/56
EX-10.9
from 10-Q 21 pages Article 1 - General Article 2 - Demise of Sublease Premises
12/34/56
EX-10.8
from 10-Q 24 pages Contingent Value Rights Agreement Between Aduro Biotech, Inc. and Computershare Trust Company, N.A. Dated as of October 2, 2020
12/34/56
EX-10.7
from 8-K 21 pages Executive Employment Agreement
12/34/56
EX-10.6
from 8-K 23 pages Executive Employment Agreement
12/34/56
EX-10.5
from 8-K 9 pages Indemnity Agreement
12/34/56
EX-10.4
from 8-K 8 pages Chinook Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.3
from 8-K 7 pages Separation Agreement and General Release of All Claims
12/34/56
EX-10.2
from 8-K 8 pages Confidential Separation Agreement
12/34/56
EX-10.1
from 8-K 8 pages Note Termination Agreement
12/34/56
EX-10.1
from S-4 46 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed
12/34/56
EX-10.3
from 8-K 1 page Blaine Templeman *** *** Re: Option Extension Dear Blaine: Sincerely, /S/ Celeste Ferber Celeste Ferber Svp, General Counsel and Secretary Acknowledged and Agreed: /S/ Blaine Templeman Date: 7/1/2020 Blaine Templeman
12/34/56
EX-10.2
from 8-K 2 pages Amendment to the Aduro Biotech, Inc. Amended and Restated Severance Plan and Summary Plan Description
12/34/56
EX-10.1
from 8-K 18 pages Amended and Restated Executive Employment Agreement
12/34/56